MindMed Announces New Employee Inducement Grants
MindMed (NASDAQ: MNMD) has announced the issuance of inducement grants to four newly hired non-executive employees. The grants consist of options to purchase 171,000 common shares of the Company, with grant dates of November 18 and December 2, 2024. The options will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over three years. The exercise price equals the closing price of MindMed shares on the last trading day before each grant. These grants were approved by MindMed's Compensation Committee on November 15, 2024, under NASDAQ Rule 5635(c)(4).
MindMed (NASDAQ: MNMD) ha annunciato l'emissione di concessioni induttive a quattro nuovi dipendenti non esecutivi. Le concessioni consistono in opzioni per l'acquisto di 171.000 azioni ordinarie della Società, con date di concessione del 18 novembre e del 2 dicembre 2024. Le opzioni matureranno in quattro anni, con il 25% che maturerà dopo un anno e il restante 75% che maturerà mensilmente nell'arco di tre anni. Il prezzo di esercizio corrisponde al prezzo di chiusura delle azioni MindMed nell'ultimo giorno di contrattazione prima di ciascuna concessione. Queste concessioni sono state approvate dal Comitato Compensazione di MindMed il 15 novembre 2024, ai sensi della Regola NASDAQ 5635(c)(4).
MindMed (NASDAQ: MNMD) ha anunciado la emisión de concesiones de inducción a cuatro nuevos empleados no ejecutivos. Las concesiones consisten en opciones para comprar 171,000 acciones ordinarias de la Compañía, con fechas de concesión del 18 de noviembre y del 2 de diciembre de 2024. Las opciones se adquirirán a lo largo de cuatro años, con el 25% adquiriéndose después de un año y el 75% restante adquiriéndose mensualmente durante tres años. El precio de ejercicio es igual al precio de cierre de las acciones de MindMed en el último día de negociación antes de cada concesión. Estas concesiones fueron aprobadas por el Comité de Compensación de MindMed el 15 de noviembre de 2024, bajo la Regla NASDAQ 5635(c)(4).
MindMed (NASDAQ: MNMD)가 4명의 신규 비상임 직원에게 유인 보상을 발행한다고 발표했습니다. 이 보상은 회사의 171,000주 보통주를 구매할 수 있는 옵션으로 구성되어 있으며, 보상 날짜는 2024년 11월 18일과 12월 2일입니다. 이 옵션은 4년에 걸쳐 차등 지급되며, 1년 후 25%가 차등 지급되고 나머지 75%는 3년에 걸쳐 매달 지급됩니다. 행사 가격은 각 보상 이전의 마지막 거래일에 해당하는 MindMed 주식의 종가와 같습니다. 이 보상은 2024년 11월 15일 MindMed 보상 위원회에서 NASDAQ 규칙 5635(c)(4)에 따라 승인되었습니다.
MindMed (NASDAQ: MNMD) a annoncé l'octroi de subventions d'incitation à quatre nouveaux employés non exécutifs. Les subventions consistent en des options d'achat de 171 000 actions ordinaires de la Société, avec des dates d'octroi des 18 novembre et 2 décembre 2024. Les options se matérialiseront sur une période de quatre ans, avec 25 % qui se matérialiseront après un an et les 75 % restants se matérialiseront mensuellement sur trois ans. Le prix d'exercice correspond au prix de clôture des actions MindMed le dernier jour de négociation avant chaque octroi. Ces subventions ont été approuvées par le Comité de Rémunération de MindMed le 15 novembre 2024, conformément à la Règle NASDAQ 5635(c)(4).
MindMed (NASDAQ: MNMD) hat die Gewährung von Anreizvergütungen an vier neu eingestellte nicht-executive Mitarbeiter bekannt gegeben. Die Zuschüsse bestehen aus Optionen zum Kauf von 171.000 Stammaktien des Unternehmens, mit Gewährungsdaten vom 18. November und 2. Dezember 2024. Die Optionen werden über einen Zeitraum von vier Jahren unverfallbar, wobei 25% nach einem Jahr und die verbleibenden 75% monatlich über einen Zeitraum von drei Jahren unverfallbar werden. Der Ausübungspreis entspricht dem Schlusskurs der MindMed-Aktien am letzten Handelstag vor jeder Gewährung. Diese Zuschüsse wurden am 15. November 2024 vom Vergabonausschuss von MindMed gemäß der NASDAQ-Regel 5635(c)(4) genehmigt.
- None.
- None.
The Options were granted as a material inducement to each employee’s employment and were approved by MindMed's Compensation Committee on November 15, 2024, in accordance with Rule 5635(c)(4) of The NASDAQ Stock Market LLC. The Options were granted outside MindMed's equity incentive plans.
About MindMed
MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241202827693/en/
For Media: media@mindmed.co
For Investors: ir@mindmed.co
Source: Mind Medicine Inc.
FAQ
How many shares are included in MindMed's (MNMD) November 2024 employee inducement grants?
What is the vesting schedule for MindMed's (MNMD) November 2024 employee stock options?
When were MindMed's (MNMD) new employee inducement grants approved?
